ascopubs.org

Outcome with total therapy 3 (TT3) compared to total therapy 2 (TT2): Role of GEP70-defined high-risk disease with trisomy of 1q21 and activation of the proteasome gene PSMD4.

Comparison of bortezomib- and lenalidomide-based therapies for the treatment of primary (AL) amyloidosis. Background: A GEP-based risk model (GEP70) defines 15% of newly diagnosed MM with a median ...
ascopubs.org

Benefit of thalidomide (THAL) in total therapy 2 (TT2) of multiple myeloma (MM) exhibiting both cytogenetic abnormalities (CA) and low-risk (LR) by gene expression profiling (GEP)

Gene expression profiling (GEP)-defined risk and molecular subgroups assessed at baseline and at relapse: Collective impact on post-relapse survival of multiple myeloma (MM) treated with total ...